Novan Provides Enrollment Update and Announces New Corporate Headquarters
19 janv. 2021 09h00 HE
|
Novan, Inc.
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to...
Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
08 janv. 2021 09h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program
21 déc. 2020 09h00 HE
|
Novan, Inc.
– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing – – Company targets initiating preclinical Investigational New Drug (IND)...
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
15 déc. 2020 09h00 HE
|
Novan, Inc.
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...
Novan Receives Approval to Transfer to Nasdaq Capital Market
04 nov. 2020 07h30 HE
|
Novan, Inc.
– Trading on Nasdaq Capital Market is expected to begin on November 5, 2020 – – Company receives additional 180-day grace period, until May 3, 2021, to satisfy the $1.00 bid price requirement to...
Novan Reports Third Quarter 2020 Financial Results and Provides Corporate Update
30 oct. 2020 07h30 HE
|
Novan, Inc.
– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 – – First to demonstrate antiviral effect...
Novan to Present at the Virtual Investor KOL Roundtable
21 oct. 2020 09h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL...
Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model
14 oct. 2020 07h00 HE
|
Novan, Inc.
- First demonstration of antiviral effect of nitric oxide-based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium - Company believes preclinical results...
Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors
24 sept. 2020 07h05 HE
|
Novan, Inc.
- John M. Gay, Vice President, Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer - James L. Bierman, seasoned industry...
Novan Provides Pipeline and Priority Development Programs Update
14 sept. 2020 09h05 HE
|
Novan, Inc.
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 - - In vitro assessments of ability of...